St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
Alex Generous, PhD
Senior Scientific Writer
Alex Generous, PhD, is a Senior Scientific Writer in the Strategic Communications, Education and Outreach Department at St. Jude.
Stories by Alex Generous
Healthy lifestyles: mitigating the risk of cognitive impairment in childhood cancer survivors
Discover how healthy lifestyles may protect cognitive abilities in childhood cancer survivors.
Spilling their guts: patient microbiomes may hold the secret to predicting outcomes after transplant
Gut microbiome predicts pediatric bone marrow transplant infections and other complications.
St. Jude avian flu hunters’ annual data collection provides context for ongoing pandemic
See how St. Jude collects avian influenza samples to stay a step ahead of the virus.
St. Jude Cloud visualizations empower scientist’s work
One scientist’s experience making high quality visualization with the St. Jude Cloud.
Gene editing holds the promise of a sickle cell cure
Explore genome editing approaches to cure sickle cell disease.
Visualization and analysis tools break down barriers for big data
St. Jude is at the forefront of creating tools to visualize and analyze genomic data.
Genetic predispositions can drive cancer but are not destiny for patients
Scientists at St. Jude are leading the way on understanding cancer predisposition and the way that inherited genetics can inform patient care.
Childhood cancer genetics: A legacy of groundbreaking work drives St. Jude forward
St. Jude Children’s Research Hospital has a rich history of research on genetics stemming from the Pediatric Cancer Genome Project and reverberating through laboratories today.
Math test points metastatic breast cancer treatment in the right direction
St. Jude computational biologists created a computational score predicting cancer drug sensitivity to HDAC6 inhibitors in a promising phase Ib clinical trial.